Literature DB >> 8373393

Inhibition of HIV-1 infection by a fusion domain binding peptide from the HIV-1 envelope glycoprotein GP41.

S Jiang1, K Lin, N Strick, A R Neurath.   

Abstract

A synthetic peptide, corresponding to the sequence (637-666) of the HIV-1 glycoprotein gp41, inhibited the replication of an array of HIV-1 strains. The peptide (637-666) selectively binds to the fusion domain at the N-terminus of gp41, suggesting that inhibition of HIV-1 infection is caused by blocking fusion of HIV-1 with cells or of infected cells with uninfected cells. Since this peptide has antiviral activity against both homologous and heterologous HIV-1 isolates and has no detectable cytotoxicity, it offers a novel approach to chemotherapy and prophylaxis of AIDS.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8373393     DOI: 10.1006/bbrc.1993.2078

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  28 in total

1.  The core of the respiratory syncytial virus fusion protein is a trimeric coiled coil.

Authors:  J M Matthews; T F Young; S P Tucker; J P Mackay
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

2.  Direct evidence that C-peptide inhibitors of human immunodeficiency virus type 1 entry bind to the gp41 N-helical domain in receptor-activated viral envelope.

Authors:  Nicole R Kilgore; Karl Salzwedel; Mary Reddick; Graham P Allaway; Carl T Wild
Journal:  J Virol       Date:  2003-07       Impact factor: 5.103

Review 3.  Biochemistry and biophysics of HIV-1 gp41 - membrane interactions and implications for HIV-1 envelope protein mediated viral-cell fusion and fusion inhibitor design.

Authors:  Lifeng Cai; Miriam Gochin; Keliang Liu
Journal:  Curr Top Med Chem       Date:  2011-12       Impact factor: 3.295

4.  Small molecules that bind the inner core of gp41 and inhibit HIV envelope-mediated fusion.

Authors:  Gary Frey; Sophia Rits-Volloch; X-Q Zhang; Robert T Schooley; Bing Chen; Stephen C Harrison
Journal:  Proc Natl Acad Sci U S A       Date:  2006-09-08       Impact factor: 11.205

5.  Viral inhibition studies on sulfated lignin, a chemically modified biopolymer and a potential mimic of heparan sulfate.

Authors:  Arjun Raghuraman; Vaibhav Tiwari; Qian Zhao; Deepak Shukla; Asim K Debnath; Umesh R Desai
Journal:  Biomacromolecules       Date:  2007-04-17       Impact factor: 6.988

6.  The ectodomain of the human T-cell leukemia virus type 1 TM glycoprotein is involved in postfusion events.

Authors:  A R Rosenberg; L Delamarre; C Pique; D Pham; M C Dokhélar
Journal:  J Virol       Date:  1997-10       Impact factor: 5.103

7.  Significant differences in cell-cell fusion and viral entry between strains revealed by scanning mutagenesis of the C-heptad repeat of HIV gp41.

Authors:  Barbara Diaz-Aguilar; Karen Dewispelaere; Hyun Ah Yi; Amy Jacobs
Journal:  Biochemistry       Date:  2013-05-07       Impact factor: 3.162

8.  Identification of a gp41 core-binding molecule with homologous sequence of human TNNI3K-like protein as a novel human immunodeficiency virus type 1 entry inhibitor.

Authors:  Yun Zhu; Lu Lu; Liling Xu; Hengwen Yang; Shibo Jiang; Ying-Hua Chen
Journal:  J Virol       Date:  2010-06-30       Impact factor: 5.103

Review 9.  Inhibition of HIV Entry by Targeting the Envelope Transmembrane Subunit gp41.

Authors:  Hyun A Yi; Brian C Fochtman; Robert C Rizzo; Amy Jacobs
Journal:  Curr HIV Res       Date:  2016       Impact factor: 1.581

10.  Combinations of the first and next generations of human immunodeficiency virus (HIV) fusion inhibitors exhibit a highly potent synergistic effect against enfuvirtide- sensitive and -resistant HIV type 1 strains.

Authors:  Chungen Pan; Lifeng Cai; Hong Lu; Zhi Qi; Shibo Jiang
Journal:  J Virol       Date:  2009-06-03       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.